1.65

1.79% -0.03

After Hours: 1.64 -0.01 -0.61%

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is traded at $1.65, with a volume of 1.91M. It is down -1.79% in the last 24 hours and down -14.51% over the past month. Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Previous Close:

$1.68

Open:

$1.69

24h Volume:

1.91M

Relative Volume:

1.39

Market Cap:

$98.19M

Revenue:

Net Income/Loss:

$-144.01M

P/E Ratio:

-0.4115

EPS:

-4.01

Net Cash Flow:

$-113.02M

1W Performance:

-38.20%

1M Performance:

-14.51%

6M Performance:

-5.71%

1Y Performance:

-84.69%

1-Day Range:

$1.60

$1.7143

1-Week Range:

$1.60

$2.01

52-Week Range:

$1.2905

$12.85

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1142)

Industry

Biotechnology (639)

Phone

(650) 980-9099

Address

1599 INDUSTRIAL ROAD, SAN CARLOS

Employee

Twitter

Next Earnings Date

2025-05-02

Latest SEC Filings

BMEA's Discussions on Twitter

Compare BMEA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMEA Biomea Fusion Inc	1.65	118.78M	0	-144.01M	-113.02M	-4.01
VRTX Vertex Pharmaceuticals Inc	407.37	104.55B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	464.95	60.36B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	557.73	59.84B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	799.56	49.07B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	327.03	35.16B	4.56B	-176.77M	225.30M	-1.7177

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-25	Initiated	Jefferies	Buy
Jun-03-25	Resumed	Piper Sandler	Overweight
Oct-09-24	Initiated	Edward Jones	Buy
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy
Sep-27-24	Upgrade	Truist	Hold → Buy
Aug-29-24	Initiated	CapitalOne	Overweight
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

10:12 AM

Real time pattern detection on Biomea Fusion Inc. stockWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - newser.com

10:12 AM

Oct 12, 2025

Is Biomea Fusion Inc. meeting your algorithmic filter criteriaJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com

Oct 12, 2025

Oct 10, 2025

Biomea Fusion Inc. stock retracement – recovery analysisWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com

Oct 10, 2025

Should you wait for a breakout in Biomea Fusion Inc.Portfolio Value Summary & Fast Exit and Entry Strategy Plans - newser.com

Oct 10, 2025

Biomea Fusion (NASDAQ:BMEA) Trading Up 6.5%What's Next? - MarketBeat

Oct 10, 2025

Tools to assess Biomea Fusion Inc.’s risk profileMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Biomea Fusion (NASDAQ:BMEA) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat

Oct 09, 2025

Does Biomea Fusion Inc. fit your quant trading model2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com

Oct 09, 2025

Oct 08, 2025

What analysts say about Biomea Fusion Inc stockBollinger Bands Signals & Free Unmatched Market Gains - earlytimes.in

Oct 08, 2025

Why Biomea Fusion (BMEA) Is Up After Positive Diabetes Data and $25M Equity Raise – And What’s Next - Yahoo Finance

Oct 08, 2025

Biomea Fusion Announces Positive Phase II Study Results - MSN

Oct 08, 2025

Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next - simplywall.st

Oct 08, 2025

Oct 07, 2025

Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher - Benzinga

Oct 07, 2025

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups - insights.citeline.com

Oct 07, 2025

Biomea’s ‘durable’ menin inhibitor advancing in hard-to-treat diabetes - BioWorld MedTech

Oct 07, 2025

Biomea Fusion: Surging On Data, Sinking On FundingI'm On The Sidelines - Seeking Alpha

Oct 07, 2025

Traders Purchase High Volume of Biomea Fusion Call Options (NASDAQ:BMEA) - MarketBeat

Oct 07, 2025

Biomea Fusion prices $25 million public offering of shares and warrants - Investing.com

Oct 07, 2025

Biomea Fusion plunges on $25 mln stock-and-warrants offering - TradingView

Oct 07, 2025

Biomea Fusion Announces Pricing of Public Offering of Securities - The Manila Times

Oct 07, 2025

D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - Nasdaq

Oct 07, 2025

$25M Offering: Biomea Fusion Prices 11.2M Shares & Warrants at $2.05 — Closing Oct 8, 2025 - Stock Titan

Oct 07, 2025

Oct 06, 2025

Biomea Fusion announces proposed public offering of securities - MarketScreener

Oct 06, 2025